Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan Biotech, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan Biotech has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The company is advancing its drug pipeline with LDR2402, a long-acting antihypertensive drug targeting AGT, which has entered Phase II clinical trials and completed the first dosing of a subject [1] - An IND application for LDR2515, a small nucleic acid drug for obesity treatment targeting INHBE, has received implied approval from the CDE [1] Group 2: Financial and Investment Details - Chengdu XianDao plans to invest up to 15 million yuan in XianYuan Biotech, which has a registered capital of 17.24 million yuan [1] - Prior to this transaction, Chengdu XianDao held a 23.20% stake in XianYuan Biotech and intends to subscribe to an additional capital increase of 24 million yuan based on a pre-investment valuation of 450 million yuan [1] - The lead investor in this financing round is Chengdu TianShi DaoYuan GuoSheng Medical Health Venture Capital Partnership, with other investors including related parties [1]

Core Insights - Chengdu Xian Dao is a leading company in the field of new molecular discovery, with a core technology platform that is its competitive advantage [2] - The company has the largest publicly known DNA-encoded compound library (DEL) globally, exceeding one trillion molecules, which has enabled over 1,000 commercial R&D projects for more than 600 clients worldwide [2] - The recent investor open day highlighted the dual innovation driven by DEL and AI drug discovery (AIDD), showcasing the company's commitment to expanding its application boundaries in complex drug targets [2][3] Technology and Innovation - The DEL technology has become a key tool for exploring first-in-class (FIC) drug targets, with the company expanding its DEL library to include protein degradation compounds, linear peptides, and cyclic peptides [2] - The HAILO platform integrates DEL, AI, and automation technologies to enhance molecular optimization efficiency through a high-throughput DMTA (Design-Synthesize-Test-Analyze) cycle [3] - The company is advancing its differentiated pipeline, with promising results from its self-developed drug HG146 for treating recurrent or metastatic adenoid cystic carcinoma and the preclinical candidate HGC290 for targeting IL-17A/AF [3] Future Development - The company aims to further explore the value potential of its trillion-level "seed library," enhance innovation capabilities, and expand the application boundaries of its core technology platforms [4] - Chengdu Xian Dao is focused on accelerating the advancement of its self-developed pipeline and collaborative projects to provide more efficient and intelligent new molecular solutions for the global pharmaceutical industry [4]